Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
INMAZEB Action Pathway
Homo sapiens
Drug Action Pathway
Atoltivimab (REGN 3470), Odesivimab (REGN 3471), and Maftivimab are monoclonal antibody (mAb) and part of the product, INMAZEB, containing three monoclonal IgG1K antibodies directed against the GP1 and GP2 glycoprotein of Zaire ebolavirus. INMAZEB, formally known as REGN-EB3, is a combination of Atoltivimab, Odesivimab, and Maftivimab in equimolar proportions. Each of them bind to a distinct portion of the GP1,2 glycoprotein and protect against ebola virus infection.It has not been established as efficacious for an other species within the Ebolavirus or Marburgvirua genera. INMAZEB is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.
Ebola virus (Zaire ebolavirus) has been responsible for at least 17 known outbreaks with an average fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is used to combat infectious diseases due to its rapid development, low toxicity, and high specificity.
Ebola virus particles expose the glycoprotein, which is comprised of a trimer of GP1, and GP2 subunit heterodimers, connected by a disulfide bond, on their surface. Atoltivimab inhibits a distinct portion of the Zaire ebolavirus envelope glycoprotein. This blocks viral endocytosis and infection of the host cells. Atoltivimab exhibits strong (<90%) neutralization of chimeric lentiviral particles expressing Ebola virus.
References
INMAZEB Pathway References
Jacob ST, Crozier I, Fischer WA 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH: Ebola virus disease. Nat Rev Dis Primers. 2020 Feb 20;6(1):13. doi: 10.1038/s41572-020-0147-3.
Pubmed: 32080199
Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285.
Pubmed: 29860496
Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G: Antibody-mediated protection against Ebola virus. Nat Immunol. 2018 Nov;19(11):1169-1178. doi: 10.1038/s41590-018-0233-9. Epub 2018 Oct 17.
Pubmed: 30333617
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings